Search
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012The objective of this study was to describe the occurrence of skin infection associated hospitalizations in children born in Western Australia (WA).
Research
Predicting regional and temporal incidence of RSV and influenza hospitalizations in a birth cohort of young Australian childrenWestern Australia experiences multiple climatic zones, influencing the epidemiology of respiratory viruses. We aimed to estimate the true incidence of respiratory syncytial virus and influenza hospitalizations across these different climatic regions using predictive modelling.
Research
Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean childrenInvasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.
Research
ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in childrenChris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear and Hearing Health
Research
Pediatric Burn Survivors Have Long-Term Immune Dysfunction With Diminished Vaccine ResponseEpidemiological studies have demonstrated that survivors of acute burn trauma are at long-term increased risk of developing a range of morbidities. The mechanisms underlying this increased risk remain unknown. This study aimed to determine whether burn injury leads to sustained immune dysfunction that may underpin long-term morbidity. Plasma and peripheral blood mononuclear cells were collected from 36 pediatric burn survivors >3 years after a non-severe burn injury (<10% total body surface area) and from age/sex-matched non-injured controls.
Research
The safety of seasonal influenza vaccines in Australian children in 2013Our objective was to examine influenza vaccine safety in Australian children aged under 10 years in 2013.
Research
Optimization is required when using linked hospital and laboratory data to investigate respiratory infectionsDespite a recommendation for microbiological testing, only 45% of children hospitalized for respiratory infections in our previous data linkage study linked...
Research
A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women.Influenza vaccination during pregnancy can prevent serious illness in expectant mothers and provide protection to newborns...
Research
Human infant memory B cell and CD4+ T cell responses to HibMenCY-TT glyco- conjugate vaccineCarrier-specific T cell and polysaccharide-specific B cell memory responses are not well characterised in infants following glyco-conjugate vaccination.